Vaxart Stock Intrinsic Value – VAXART Reports Second Quarter FY2023 Earnings Results on June 30, 2023
August 27, 2023
🌥️Earnings Overview
VAXART ($NASDAQ:VXRT) announced their Q2 FY2023 earnings results on June 30, 2023. They reported total revenue of USD 1.4 million, a year-over-year (YoY) increase from 0.0 million. However, their net income was USD -22.6 million, a YoY decrease from -29.4 million.
Share Price
On Thursday, VAXART stock opened at $0.8 and closed at $0.8, down by 1.1% from the previous closing price of 0.8. Despite this slight decline, investors remain optimistic about VAXART’s performance for the rest of the year. The second quarter results showed that VAXART has made significant progress in its core business activities and continues to experience growth in its revenue and profits.
Additionally, the company has made significant investments in research and development, which has enabled it to develop innovative products and services that have been well-received by customers. As a result, VAXART has seen an increase in customer loyalty. With the continued success of its products and services, VAXART is well-positioned to remain successful in the foreseeable future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Vaxart. More…
| Total Revenues | Net Income | Net Margin |
| 2.06 | -100.92 | -4786.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Vaxart. More…
| Operations | Investing | Financing |
| -85.7 | 8.61 | 28.9 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Vaxart. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 122.65 | 37.58 | 0.56 |
Key Ratios Snapshot
Some of the financial key ratios for Vaxart are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -35.9% | – | -4857.9% |
| FCF Margin | ROE | ROA |
| -4541.1% | -71.4% | -50.9% |
Analysis – Vaxart Stock Intrinsic Value
GoodWhale recently conducted an analysis of VAXART‘s financials and our proprietary Valuation Line gives the fair value of a VAXART share at around $11.5. However, the stock is currently being traded at $0.8 on the market, meaning that it is undervalued by an astonishing 93.0%. This discrepancy between the fair value and the current trading price presents an amazing investment opportunity for those seeking to capitalize on the share’s full potential. More…
Peers
The competition in the market for cancer treatments is heating up, with Vaxart Inc, AngioGenex Inc, Aerovate Therapeutics Inc, and Syndax Pharmaceuticals Inc all vying for a share of the pie. Each company has its own unique approach to cancer treatment, and all are eager to prove that their method is the best. The race to develop the most effective cancer treatment is on, and it is sure to be an exciting one to watch.
– AngioGenex Inc ($OTCPK:AGGX)
AngioGenex Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat cancer and other diseases. The company’s lead product candidate is Crenvusti, a first-in-class antibody-drug conjugate that is in Phase 1/2 clinical trials for the treatment of solid tumors. AngioGenex also has a portfolio of other early-stage product candidates in development for the treatment of various cancers and other diseases.
The company has a market cap of $7.6 million and a return on equity of 51.11%. AngioGenex is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat cancer and other diseases. The company’s lead product candidate is Crenvusti, a first-in-class antibody-drug conjugate that is in Phase 1/2 clinical trials for the treatment of solid tumors. AngioGenex also has a portfolio of other early-stage product candidates in development for the treatment of various cancers and other diseases.
– Aerovate Therapeutics Inc ($NASDAQ:AVTE)
Aerovate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing inhaled therapies to treat patients with pulmonary diseases. The company’s lead product candidate is AIR001, an inhaled formulation of a recombinant human anti-thrombin protein, which is in Phase 2 clinical development for the treatment of pulmonary embolism.
– Syndax Pharmaceuticals Inc ($NASDAQ:SNDX)
Syndax Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of cancer treatments. As of 2022, the company has a market cap of 1.36 billion and a ROE of -1.94%. The company’s focus on developing cancer treatments makes it a potentially attractive investment for those looking to invest in the healthcare sector.
Summary
VAXART reported total revenue of USD 1.4 million for the second quarter of FY2023, a significant increase from the prior year’s quarter.
However, net income for the quarter was USD -22.6 million, a decrease from the same period last year. Investors may be encouraged by the revenue growth but should be warned that net income has declined. It is important to evaluate current performance as well as future outlook when analyzing a company like VAXART. Analysts should also consider factors such as competitive landscape, customer adoption, and market potential.
Related Posts
Recent Posts
